{"id":1551,"date":"2024-08-30T21:56:32","date_gmt":"2024-08-30T19:56:32","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/news-from-science-and-practice\/"},"modified":"2026-01-28T15:12:51","modified_gmt":"2026-01-28T14:12:51","slug":"news-from-science-and-practice","status":"publish","type":"page","link":"https:\/\/studienportal-eierstockkrebs.de\/en\/news-from-science-and-practice\/","title":{"rendered":"News from science and practice"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

News<\/strong>
News from science and practice<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

First results of the NAPISTAR 1-01 study<\/a><\/h3><\/header>
\n

New targeted therapy investigated for platinum-resistant ovarian cancer At ESGO 2026, the first results of an early clinical trial of a new drug called TUB-040 in patients with platinum-resistant ovarian...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Highlights from ESGO 2026 and new approval!<\/a><\/h3><\/header>
\n

We attended the ESGO conference in Copenhagen and saw the presentation of the study results, which had already received FDA approval in February! Keytruda + Paclitaxel as a new option...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New final data: Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer<\/a><\/h3><\/header>
\n

New final data: Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer The final results of the AGO-OVAR 2.29 (ENGOT-ov34) study were published in December 2025. This large...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 27- WoO<\/a><\/h3><\/header>
\n

AGO-OVAR 27 – WoO WoO: Window of Opportunity study on olaparib and durvalumab in histologically proven EOC Cohort A of the AGO-ovar 27 study has been fully recruited since January...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Study objective achieved! – Results of the ROSELLA study<\/a><\/h3><\/header>
\n

New findings on the treatment of platinum-resistant ovarian cancer – results of the ROSELLA study At the end of January, the pharmaceutical company Corcept Therapeutics published a press release on...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

News for patients with platinum-resistant ovarian cancer<\/a><\/h3><\/header>
\n

News for patientswith platinum-resistant ovarian cancer The pharmaceutical company Eli Lilly recently received approval from the US Food and Drug Administration with a Breakthrough Therapy Designation for a new drug...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

Expression XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30\/ Expression XVIII (18) INTERNATIONAL SURVEY ON THE IMPACT OF CRISES ON PATIENTS WITH GYNECOLOGICAL TUMORS Anxiety is a central issue in cancer patients with gynecologic diseases and can...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EXPRESSION IX (9)<\/a><\/h3><\/header>
\n

NOGGO S20 \/ ENGOTgyn4 – EXPRESSION IX (9) Long-term survival with gynecological cancer \/ Langzeit\u00fcberlebende mit gyn\u00e4kologischen Krebserrankungen Based on the experience with Expression VI – Carolin meets HANNA, a...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S19 – EXPRESSION VIII (8)<\/a><\/h3><\/header>
\n

NOGGO S19 – EXPRESSION VIII (8) For patients with a low-grade ovarian carcinoma (group A) or a borderline tumor of the ovary (group B – closed). Serous ovarian carcinoma is...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EXPRESSION VI (6)<\/a><\/h3><\/header>
\n

NOGGO S13 \/ ENGOT-ov40 – EXPRESSION VI (6)CAROLIN MEETS HANNA For patients with ovarian, fallopian tube and peritoneal cancer who were diagnosed at least 5 years ago NEW: Instead of...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-ov83 \/ CATALINA-2<\/a><\/h3><\/header>
\n

ENGOT-ov83 \/ CATALINA-2 Therapeutic study to evaluate the efficacy and safety of the new compound TORL-1-23 in patients with advanced, platinum-resistant ovarian cancer CATALINA-2 is an international phase 2 trial...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – HELP-ER<\/a><\/h3><\/header>
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – HELP-ER OBSERVATIONAL STUDY ON HE4 SERUM LEVELS IN THE BLOOD OF PATIENTS WITH FIRST RECURRENCE OF OVARIAN CANCER The HELP-ER study was designed to improve the treatment...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301<\/a><\/h3><\/header>
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 CLINICAL STUDY ON RECURRENT LOW-GRADE SEROUS OVARIAN CANCER The AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 is a randomized, open-label phase III trial...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO ov54 – SCOUT-1<\/a><\/h3><\/header>
\n

NOGGO ov54 – Scout 1 Observational study to collect data from the everyday routine of patients with ovarian cancer undergoing initial therapy SCOUT-1 is a non-interventional study, a so-called observational...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

N-PLUS<\/a><\/h3><\/header>
\n

NOGGO ov53\/ ENGOT-ov62 – N-Plus The world’s first study with the aim of reducing the number of chemotherapy cycles and thus the duration of chemotherapy in patients who have undergone...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NIS CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN For patients with platinum-sensitive ovarian cancer who have no contraindications to niraparib This non-interventional observational study aims to investigate the long-term treatment with niraparib...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S15 – FraStROC<\/a><\/h3><\/header>
\n

NOGGO S15 – FraStROC Study for patients with recurrent or relapsed ovarian cancer. STUDY FOR PATIENTS WITH RECURRENT OR RELAPSED OVARIAN CANCER The FraStROC study is a non-interventional, prospective, multicenter...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 28 \/ ENGOT-OV57<\/a><\/h3><\/header>
\n

AGO-OVAR 28 \/ ENGOT-ov57 A randomized open-label phase III study evaluating niraparib alone versus the combination of niraparib and bevacizumab in patients receiving chemotherapy for newly diagnosed advanced ovarian cancer...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EXPRESSION XX (20)<\/a><\/h3><\/header>
\n

NOGGO S33\/ Expression XX (20) SURVEY AMONG PATIENTS WITH GYNECOLOGICAL TUMORS ON HOW TO DELIVER BAD NEWS Breaking bad news is an essential part of everyday medical practice, especially in...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New study data from ESMO 2025 – Immunotherapy brings survival benefit in platinum-resistant ovarian cancer for the first time<\/a><\/h3><\/header>
\n

New study data from ESMO 2025Immunotherapy provides first survival benefit in platinum-resistant ovarian cancer A press release on the initial results of the ENGOT-ov65\/KEYNOTE-B96 trial was published in May 2025,...<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

The most important ASCO results for ovarian cancer<\/a><\/h3><\/header>
\n

The most important ASCO results 2025 for ovarian cancer Yesterday, the 26th NOGGO Update on Gynecologic Oncology took place, where important studies on ovarian cancer from ASCO 2025 were presented....<\/p>read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

NewsNews from science and practice NIS Niraparib \u2013 NOGGO-ov45 \u2013 CAROLIN NIS Niraparib \u2013 NOGGO-ov45 \u2013 CAROLIN F\u00fcr Patientinnen mit platinsensitivem Eierstockkrebs, die keine Gegenanzeigen von Niraparib aufweisen Diese nicht-interventionelle Beobachtungsstudie soll die Langzeittherapie mit Niraparib bei Patientinnen mit platinsensitivem Eierstockkarzinom,… read more EXPRESSION IX (9) NOGGO S20 \/ ENGOTgyn4 \u2013 EXPRESSION IX (9) Longterm […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1551","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=1551"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1551\/revisions"}],"predecessor-version":[{"id":1554,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/pages\/1551\/revisions\/1554"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=1551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}